SEPSECS
O-phosphoseryl-tRNA(Sec) selenium transferase
Also known as: SecS, SLA, SLA-p35, SLA/LP, SPCS_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9HD40
- Gene
- SEPSECS
- Ensembl
- ENSG00000109618
- Chromosome
- 4
- Canonical length
- 501 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins
- Subcellular location
- Vesicles
- Quaternary structure
- Homotetramer
OverviewNCBI Gene
The amino acid selenocysteine is the only amino acid that does not have its own tRNA synthetase. Instead, this amino acid is synthesized on its cognate tRNA in a three step process. The protein encoded by this gene catalyzes the third step in the process, the conversion of O-phosphoseryl-tRNA(Sec) to selenocysteinyl-tRNA(Sec).[provided by RefSeq, Mar 2011]
Canonical amino-acid sequenceUniProt
501 residues, UniProt reviewed canonical sequence.
>Q9HD40|SEPSECS
1 MNRESFAAGE RLVSPAYVRQ GCEARRSHEH LIRLLLEKGK CPENGWDEST LELFLHELAI
61 MDSNNFLGNC GVGEREGRVA SALVARRHYR FIHGIGRSGD ISAVQPKAAG SSLLNKITNS
121 LVLDIIKLAG VHTVANCFVV PMATGMSLTL CFLTLRHKRP KAKYIIWPRI DQKSCFKSMI
181 TAGFEPVVIE NVLEGDELRT DLKAVEAKVQ ELGPDCILCI HSTTSCFAPR VPDRLEELAV
241 ICANYDIPHI VNNAYGVQSS KCMHLIQQGA RVGRIDAFVQ SLDKNFMVPV GGAIIAGFND
301 SFIQEISKMY PGRASASPSL DVLITLLSLG SNGYKKLLKE RKEMFSYLSN QIKKLSEAYN
361 ERLLHTPHNP ISLAMTLKTL DEHRDKAVTQ LGSMLFTRQV SGARVVPLGS MQTVSGYTFR
421 GFMSHTNNYP CAYLNAASAI GMKMQDVDLF IKRLDRCLKA VRKERSKESD DNYDKTEDVD
481 IEEMALKLDN VLLDTYQDAS SLocalizationUniProt · AlphaFold · HPA
Whether an antibody against SEPSECS can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.27
- Highest tissue expression
- 24 nTPM
Expression across tissuesHPA
Tissue
- liver: 24 nTPM
- kidney: 7.7 nTPM
- thymus: 4.8 nTPM
- duodenum: 4.6 nTPM
- small intestine: 4.6 nTPM
- breast: 4 nTPM
Single-cell type
- hepatocytes: 74 nCPM
- tuft cells: 69 nCPM
- early primary spermatocytes: 56 nCPM
- proximal tubule cells: 45 nCPM
- enterocytes: 45 nCPM
- sertoli cells: 43 nCPM
Immune cell
- intermediate monocyte: 0.6 nTPM
- classical monocyte: 0.2 nTPM
- MAIT T-cell: 0.2 nTPM
- memory CD4 T-cell: 0.2 nTPM
- myeloid DC: 0.2 nTPM
- naive CD4 T-cell: 0.2 nTPM
Brain region
- white matter: 1.8 nTPM
- cerebral cortex: 1.7 nTPM
- medulla oblongata: 1.4 nTPM
- pons: 1.3 nTPM
- thalamus: 1.3 nTPM
- hypothalamus: 1.2 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about SEPSECS.
Disease | AllUniProt
Conditions SEPSECS is implicated in, by any mechanism.
- Pontocerebellar hypoplasia 2D (PCH2D) MIM:613811
Disease | GeneticClinVar
105 pathogenic / likely-pathogenic of 680 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Pontocerebellar hypoplasia type 2D
- Inborn genetic diseases
- Pontoneocerebellar hypoplasia
- 6 conditions
- 7 conditions
Disease | ImmuneIEDB
Conditions an epitope on SEPSECS was assayed in.
- autoimmune hepatitis T cell
Disease | AutoantibodyPubMed
Conditions in which antibodies against SEPSECS are reported. Each links to that disease's full target list.
ReferencesPubMed · IEDB
Publications for SEPSECS from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
25 publications
- Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen.
1987 · Lancet · RCR 10.3 · 346 citations - Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis.
2000 · Lancet · RCR 5.3 · 225 citations - Clonal analysis of SepSecS-specific B and T cells in autoimmune hepatitis.
2025 · J Clin Invest · RCR 3.4 · 11 citations - Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis.
1999 · J Hepatol · RCR 3 · 112 citations - Characterization of liver cytokeratin as a major target antigen of anti-SLA antibodies.
1990 · J Hepatol · RCR 2.7 · 70 citations
Show 20 more
- Integrative molecular profiling of autoreactive CD4 T cells in autoimmune hepatitis.
2020 · J Hepatol · RCR 2.5 · 64 citations - Relation between autoimmune liver diseases and viral hepatitis: clinical and serological characteristics in 859 patients.
1995 · Z Gastroenterol · RCR 1.7 · 55 citations - Antibodies to soluble liver antigen in patients with various liver diseases: a multicentre study.
2013 · Liver Int · RCR 1.4 · 35 citations - Evaluation of immunoserological detection of anti-liver kidney microsomal, anti-soluble liver antigen and anti-mitochondrial antibodies.
2023 · Sci Rep · RCR 0.8 · 6 citations - Identification of rat targets of anti-soluble liver antigen autoantibodies by serologic proteome analysis.
2003 · Clin Chem · RCR 0.7 · 28 citations - SLA/LP/tRNP((Ser)Sec) antigen in autoimmune hepatitis: identification of the native protein in human hepatic cell extract.
2010 · J Autoimmun · RCR 0.6 · 22 citations - Anti-soluble liver antigen (SLA) antibodies in chronic HCV infection.
2004 · Autoimmunity · RCR 0.6 · 20 citations - Differentiation between autoimmune hepatitis and hepatitis C virus related liver disease.
1993 · Z Gastroenterol · RCR 0.5 · 13 citations - Identification of T cell epitopes on soluble liver antigen in Chinese patients with auto-immune hepatitis.
2011 · Liver Int · RCR 0.5 · 18 citations - Autoimmune hepatitis-specific antibodies against soluble liver antigen and liver cytosol type 1 in patients with chronic viral hepatitis.
2007 · J Autoimmune Dis · RCR 0.5 · 17 citations - Antibodies to soluble liver antigen and alpha-enolase in patients with autoimmune hepatitis.
2004 · J Autoimmune Dis · RCR 0.5 · 17 citations - Prognostic Implications of Antibodies to Soluble Liver Antigen in Autoimmune Hepatitis: A PRISMA-Compliant Meta-Analysis.
2015 · Medicine (Baltimore) · RCR 0.5 · 11 citations - Drug-induced hepatitis superimposed on the presence of anti-SLA antibody: a case report.
2008 · J Med Case Rep · RCR 0.1 · 4 citations - [Coincidence of a chronic Hepatitis C and an autoimmune Hepatitis Type 3 - successful therapy with the new direct-acting antiviral agents].
2016 · Z Gastroenterol · RCR 0.1 · 1 citations - [Clinical and laboratory characteristics of anti-soluble liver antigen/liver-pancreas (SLA/LP) autoantibody positive liver disease patients].
2005 · Zhonghua Gan Zang Bing Za Zhi - [A retrospective study on the role of antibodies against soluble liver antigen (anti-SLA antibodies) and other autoantibodies in the diagnostics of autoimmune hepatitis].
2006 · Ned Tijdschr Geneeskd - Autoimmune hepatitis with anti SLA antibodies.
2011 · Acta Gastroenterol Belg - [Autoimmune hepatitis].
2013 · Klin Med (Mosk) - [Autoimmune hepatitis].
1994 · Rev Prat - Association of dermatomyositis and autoimmune hepatitis: A case report.
2025 · Hepatol Forum
Reference: T cellIEDB
2 publications
- Clonal analysis of SepSecS-specific B and T cells in autoimmune hepatitis.
2025 · J Clin Invest · RCR 3.4 · 11 citations - Identification of T cell epitopes on soluble liver antigen in Chinese patients with auto-immune hepatitis.
2011 · Liver Int · RCR 0.5 · 18 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.99
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.02
- DepMap mean gene effect
- -0.53
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- selenocysteine incorporation
- conversion of seryl-tRNAsec to selenocys-tRNAsec
Molecular functions
- tRNA binding
- O-phosphoseryl-tRNA(Sec) selenium transferase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Pyridoxal phosphate-dependent transferase, major domain
- Pyridoxal phosphate-dependent transferase
- SepSecS/SepCysS family
- Peroxidases heam-ligand binding site
- O-phosphoseryl-tRNA(Sec) selenium transferase
- O-phosphoseryl-tRNA(Sec) selenium transferase, SepSecS
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SEPSECS as an antibody target. Whether an autoantibody or antibody against SEPSECS could matter depends on whether native SEPSECS is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SEPSECS is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label SEPSECS as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...